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ABSTRACT
Aims To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opi-
oids in Australia.Design Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia
in November 2018. Setting Sydney, Melbourne and Hobart. Participants A total of 402 people who regularly use
opioids interviewed December 2017 toMarch 2018.Measurements Primaryoutcome concerned the proportion of par-
ticipants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly
injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demo-
graphic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosing
setting, unsupervised doses, out-of-pocket expenses and travel distance). Findings Sixty-eight per cent [95% confidence
interval (CI) = 63–73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to re-
port being younger [26–35 versus > 55 years; odds ratio (OR) = 3.16, 95% CI = 1.12–8.89; P = 0.029], being female
(OR = 1.67, 95% CI = 1.04–2.69; P = 0.034), < 10 years school education (OR = 1.87, 95% CI = 1.12–3.12; P =
0.016) and past-month heroin (OR = 1.81, 95% CI = 1.15–2.85; P = 0.006) and methamphetamine use (OR = 1.90,
95% CI = 1.20–3.01; P = 0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% pre-
ferred weekly and 39% preferred monthly. Among OAT recipients (n = 255), believing XR-buprenorphine was a good
treatment option was associated with shorter treatment episodes (1–2 versus ≥ 2 years; OR = 3.93, 95% CI = 1.26–
12.22; P = 0.018), fewer unsupervised doses (≤ 8 doses past-month versus no take-aways; OR = 0.50; 95% CI = 0.27–
0.93; P = 0.028) and longer travel distance (≥ 5 versus < 5 km; OR = 2.10, 95% CI = 1.20–3.65; P = 0.009). Sixty-
nine per cent reported ‘no problems or concerns’ with potential differences in availability, flexibility and location of XR-
buprenorphine. Conclusions Among regular opioid users in Australia, perceptions of extended-release buprenorphine
as a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)conve-
nience of current opioid agonist treatment.
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INTRODUCTION
The mainstays of opioid agonist treatment (OAT), meth-
adone and buprenorphine (± naloxone), are well
established as effective treatments for opioid use disorder
[1,2]. OAT interrupts the cycle of intoxication and
withdrawal, greatly reducing illicit opioid use, crime,
overdose and mortality risk [3–5]. Despite these clear
health benefits, OAT carries some risks, including
non-adherence, injection of medication intended for
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oral/sublingual administration, diversion and overdose
(e.g. [6–8]).
Newer extended-release (XR) buprenorphine formula-
tions for the treatment of opioid use disorder have been de-
veloped, including subdermal implants and subcutaneous
injections [9]. In the United States, 6-monthly subdermal
buprenorphine implants have been approved for the treat-
ment of opioid use disorder since 2016 [9,10]. More re-
cently, once-monthly XR-buprenorphine subcutaneous
injections have been approved in the United States [11]
and once-weekly and once-monthly subcutaneous injec-
tions have been approved in Australia and Europe [11,12].
An emphasis upon supervised daily dosing is a feature of
OAT in many countries (e.g. [13–16]), including Australia,
but people in treatment often state that attendance for su-
pervised dosing is burdensome and restrictive on many
other aspects of daily life [17], especially if significant travel
time is required. In addition, Australian OAT clients fre-
quently pay the costs of pharmacy dispensing fees [18]. Al-
though the out-of-pocket client costs associated with XR-
buprenorphine are not yet clear, eliminating the need for
frequent attendance at the pharmacy or clinic for medica-
tion dosing may increase the time available for work and
education [9,17]. XR-buprenorphine delivered by a
health-care professional may also reduce both diversion of
the medication and use via unintended routes of adminis-
tration [9]. It is important to understand howchanges such
as these are perceived among the potential client popula-
tion (e.g. [19, 20]) to inform the implementation into treat-
ment programmes of this formulation.
To date, two studies have been conducted internation-
ally, examining clients’ perspectives on the impacts of
changes to the frequency of dosing for XR-buprenorphine
and potential safety concerns [21,22]. These qualitative
studies indicate that perceptions of XR-buprenorphine in-
jections and implants may be influenced by a range of
physical, psychological and social factors [22]. Our study
aims to develop an understanding of the perceptions of
XR-buprenorphine in a larger sample of potential clients
and examine correlates of these perceptions.
The specific aims of this study are to examine:
1 The proportion of people who use opioids regularly who
consider that XR-buprenorphine would be a good treat-
ment option for them;
2 The correlates of perceiving XR-buprenorphine as a
good treatment option;
3 Preferences for aweekly versusmonthly injection of XR-
buprenorphine and correlates of such preferences;
4 Whether current OATand features of treatment delivery
are associated with perceiving XR-buprenorphine as a
good treatment option (among current OAT clients);
and
5 The perceived advantages and disadvantages of XR-
buprenorphine.
METHODS
Study design
In this cross-sectional study to evaluate perception of XR-
buprenorphine, we enrolled participants from three Aus-
tralian jurisdictions (Sydney, New South Wales; Mel-
bourne, Victoria; and Hobart, Tasmania) between
December 2017 andMarch 2018. These jurisdictions were
chosen to ensure adequate representation of the mix of
Australian treatment settings (public clinics, general
practice/private prescribers and community pharmacy
dosing) [23] within the available budget and time con-
straints. No formal sample size calculations were under-
taken, as the study objectives were descriptive. This
survey was conducted prior to the registration andmarket-
ing of XR-buprenorphine injection formulations in
Australia, although a small number of Australian sites
had participated in international Phase 3 trials of a once-
weekly or once-monthly buprenorphine injection during
2016–17. The STROBE checklist is provided in Supporting
information, Appendix S1. The analyses were not pre-
registered; therefore, the results should be considered
exploratory.
Ethics
This study was reviewed and approved by South Eastern
Sydney Local Health District Human Research Ethics Com-
mittee 17/224 (HREC/17/POWH/486), Tasmania Health
and Medical HREC (H0017051) and the Alfred Hospital
(515/17).
Participants
To be eligible for the study, participants were aged 18 years
or older and able to provide voluntary and informed con-
sent; andwere either using illicit/extra-medical opioids reg-
ularly or currently receiving treatment for opioid use
disorder (or both). In this study, regular opioid use was op-
erationalized as use of any opioid (including heroin use or
the extra-medical use of pharmaceutical opioids) on at
least 21 of the past 28 days.
Procedure
Participants were recruited from a range of settings, in-
cluding needle and syringe programmes, OAT services,
snowballing (where eligible participants promote the study
via their personal networks [24]) and word-of-mouth. The
study was advertised at services using posters and fliers,
but service staff were not directly involved in recruitment.
Interested participants contacted the study team directly
and were screened for eligibility over the telephone.
Interviewers met participants in person to obtain con-
sent and conduct the interview. Interviews were
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conducted using a computer-assisted structured interview
schedule administered via computer tablets. Interviews
were conducted by trained interviewers who, at a mini-
mum, received training in responding to adverse events
such as participant distress or suicidal ideation. The inter-
views took approximately 1 hour to complete, and partici-
pants were reimbursed $AUD50 for their time and out-of-
pocket expenses.
Measures
Perceptions of XR-buprenorphine
Interviewers read a brief description of XR-buprenorphine
to all participants (Supporting information, Appendix S2),
followed by questions examining perceptions of XR-
buprenorphine. The main outcome in the current study
is the item ‘Do you think a long-acting injection of
buprenorphine (‘depot’) would be a good treatment option
for you personally?’ (yes/no/not sure).
Participants were also asked a range of additional items
to elicit their perceptions of XR-buprenorphine (see
Supporting information, Appendix S2 for the full module
of questions and exact item wording), including:
• Preferences for the frequency of XR-buprenorphine in-
jections based on rating the likelihood that they would
use weekly versusmonthly XR-buprenorphine injections
on a Likert scale from 0–10, where 0 = ‘not at all likely’
and 10 = ‘extremely likely’.
• Perceptions of the advantages and disadvantages of
treatment with XR-buprenorphine from a pre-
determined list (multiple responses were allowed),
followed by an open-ended prompt for ‘Other (specify)’.
• Willingness to change doctors for treatment with XR-
buprenorphine (yes/no/not sure).
• Distance willing to travel for treatment with XR-
buprenorphine measured in travel time (response cate-
gories: ‘not interested/not willing to travel at all’, ‘less
than 15 minutes’, ‘15–30 minutes’, ‘30–45 minutes’
‘45–60 minutes’, ‘60–90 minutes’ or ‘more than 90
minutes’).
• The extent to which pre-determined features of treat-
ment with XR-buprenorphine would raise problems or
concerns for them personally (‘no problems or
concerns’/‘minor problems or concerns’/‘major prob-
lems or concerns’).
Demographic and clinical characteristics
Participants’ age, gender, country of birth (additional data
on language and cultural background were not collected),
employment status, main source of income, highest level of
education and whether or not they were homeless were re-
corded. ‘Homelessness’ included primary (e.g. sleeping
rough), secondary (e.g. couch-surfing or hostel) and
tertiary homelessness (e.g. insecure accommodation such
as a caravan) [25]. Participants were asked about life-time
substance use and days of use in the past 28 days. ‘Hazard-
ous drinking’was defined as meeting the cut-point score of
4 for males and 3 for females on the Alcohol Use Disorder
Identification Test, version C (AUDIT-C) [26].
Treatment history
Participants were asked about their life-time engagement
with a range of possible treatments for opioid use disorder,
including OAT. Those currently receiving OAT were asked
about the characteristics of their current treatment epi-
sode, including medication-type, length of current treat-
ment episode (years), dosing setting, prescriber setting,
main opioid of concern at treatment entry, scheduled
doses, missed doses, supervised/unsupervised doses, out-
of-pocket expenses (dispensing fees, appointment fees,
travel costs) and distance travelled for dosing.
Analyses
Data were analyzed using Stata SE version 15.1. Variables
were summarized using frequencies and valid percentages,
as appropriate. Missing cases for individual variables are re-
ported in the table notes.
Demographic characteristics and substance use of the
sample were examined according to (a) whether or not
participants believed XR-buprenorphine might be a good
treatment option for them (primary study outcome) and
(b) whether or not participants were currently receiving
OAT (additional analyses; Supporting information, Appen-
dix S4). Multiple logistic regression controlling for age and
gender was used to calculate adjusted odds ratios (aORs)
and 95% confidence intervals (95% CI). Characteristics of
current OAT episode (among current OAT clients) were ex-
amined according to whether or not participants believed
XR-buprenorphine was a good treatment option for them
using multiple logistic regression models controlling for
age, gender and length of current treatment episode.
Individual differences in Likert scale ratings for weekly
versus monthly (i.e. the likelihood rating for weekly injec-
tions minus the likelihood rating for monthly injections)
were used to determine whether participants held a prefer-
ence for one over the other. Where the difference equalled
zero, the preference was coded as ‘no preference’. Multino-
mial regression was used to examine whether age, gender,
past heroin use, past-month methamphetamine use
and current OAT were associated with displaying no
preference, a preference for weekly or a preference for
monthly injections. In order to compare groups with a
preference for weekly versus monthly injections, the larger
of these two groups was selected as the referent group
(preference for monthly injections) (Supporting informa-
tion, Appendix S5).
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The pre-determined list of advantages and disadvan-
tages of XR-buprenorphine was analyzed using percent-
ages. Where participants endorsed ‘Other (specify)’, free
text responses were subsequently re-categorized where ap-
propriate, or new categories were created and listed by fre-
quency. Additional multiple logistic regression models
(controlling for age and gender) were conducted to exam-
ine for whether perceptions of XR-buprenorphine differed
according to whether or not participants were currently
receiving OAT (Supporting information, Appendix S6).
To check for heterogeneity in key characteristics across
the three survey sites (New South Wales, Victoria and
South Australia), we (a) examined differences in the pri-
mary outcome (‘Perceptions that XR-buprenorphine was
a good treatment option for them’) and (b) included any
relevant interaction terms (jurisdiction × characteristic)
in each of the logistic regressions shown in Table 1 below.
These analyses indicated that there was no substantial ev-
idence of heterogeneity; therefore, the results can be taken
as representing similar Australian jurisdictions.
RESULTS
A total of 402 participants were interviewed in this study
[mean age 42 years, standard deviation (SD) = 8.9, 37% fe-
male]; demographic and other characteristics are summa-
rized in Supporting information, Appendix S3. The
majority of the sample were Australian-born (85%).
Among the 62 participants born elsewhere, 32% were
from North-West Europe, 19% Oceania, 19% South-East
Asia, 11% South and Eastern Europe, 10% North Africa
and Middle East and 5% other regions. The vast majority
(90%) of participants had life-time experience of OAT
(methadone or buprenorphine ± naloxone) and 67% were
currently receiving OAT (56% methadone; 11%
buprenorphine ± naloxone). Participants currently receiv-
ing OAT were more likely to be female and were less likely
to report past-month use of morphine or oxycodone; how-
ever, there were no other significant differences between
the in- and out-of-treatment groups (Supporting informa-
tion, Appendix S4).
Two-thirds (68%) of the total sample believed that XR-
buprenorphine was a good treatment option for them after
the nature of the treatment was explained to them. Partic-
ipants who believed XR-buprenorphine was a good treat-
ment option for them were more likely to be aged 26–
35 years (versus > 55 years), female and had completed
fewer years of education; they were more likely to report
past-month heroin and methamphetamine use (Table 1).
Neither life-time nor current OAT were associated with
participants’ believing that XR-buprenorphine was a good
treatment option for them (Table 1; see Supporting infor-
mation, Appendix S7 for complete responses, i.e. not
dichotomized).
Among the total sample, 15% of participants reported
being ‘not at all likely’ (0 on a 0–10 Likert scale) to use a
weekly buprenorphine injection and 14% reported being
‘not at all likely’ to use a monthly buprenorphine injection,
with no differences according to whether or not they were
currently receiving OAT (Fig. 1, Supporting information,
Appendix S5). Conversely, 27% of participants reported be-
ing ‘extremely likely’ (10 on a 0–10 Likert scale) to use a
weekly buprenorphine injection and 47% reported being
‘extremely likely’ to use amonthly buprenorphine injection
(Fig. 1). Individual differences in Likert scale scores indi-
cated that 54% of participants reported no difference in
their preference for monthly versus weekly injections, 7%
showed a preference for weekly injections and 39% showed
a preference for monthly injections. There were no signifi-
cant associations between demographic, drug use or treat-
ment variables and having a preference for weekly or
monthly injections (Supporting information, Appendix S5).
Among people currently receiving OAT (n = 255), par-
ticipants who believed XR-buprenorphine was a good
treatment option for them reported a shorter current treat-
ment episode (i.e. higher odds of being in treatment 1–
2 years versus ≥ 2 years), travelling greater distances for
dosing and fewer unsupervised (or ‘take-away’) doses
(Table 2). Current OAT medication, prescriber setting, dos-
ing setting and out-of-pocket costs were not associated
with participants’ perceptions that XR-buprenorphine
was a good treatment option for them.
The majority of all participants reported perceived ad-
vantages of XR-buprenorphine from a pre-specified list
(Table 3), most commonly ‘attend treatment services less
frequently’, ‘gives memore time to do other things’, ‘allows
travel for work or holidays’, ‘prevents cravings for opioids’,
‘feel in control of my treatment’ and ‘suppresses with-
drawal symptoms for a long time’ (endorsed by 62–76%
of the sample). Additional advantages reported as ‘Other
(specify)’ included convenience (n = 4), cost savings
(n=2), enhanced self-determination (n=2), enhanced pri-
vacy (n = 2), avoiding the stigma of attending for OAT
(n= 2), missing fewer doses (n= 2) and removing the logis-
tical challenges of attending for daily dosing with young
children (n = 2).
Potential disadvantages of XR-buprenorphine were re-
ported less frequently. The most commonly reported disad-
vantages from a pre-specified list (Table 3) were ‘might not
hold people for the whole period between doses’ (40%) and
‘blocks the effects of other opioids’ (26%). Additional disad-
vantages reported as ‘Other (specify)’ included anxiety
about the possible side effects (n = 6), not liking
buprenorphine (n = 5), pain management concerns
(n = 4), concerns about continued drug use (n = 2), con-
cern that the injectionmay act as a ‘trigger’ for illicit opioid
use (n= 2), concern about the risks of overdose (n = 2) and
not wishing to be injected as a treatment modality (n = 1).
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Table 1 Demographic, clinical and substance use profile of the study sample according to whether participants perceived XR-
buprenorphine was a good treatment option for them (n = 382).
Perceived XR-buprenorphine was a good
treatment option for them, n = 382a
Adjusted odds ratiosdNo/not sure
n = 122 (32%)
Yes
n = 260 (68%)
n (%) n (%) aOR (95% CI) P-value
Demographic characteristics
Age, years (n = 382)
≤ 25 5 (38%) 8 (62%) 1.66 (0.39–1.07) 0.491
26–35 21 (25%) 63 (75%) 3.16 (1.12–8.89) 0.029
36–45 50 (31%) 112 (69%) 2.44 (0.93–6.43) 0.070
46–55 36 (35%) 68 (65%) 2.18 (0.81–5.89) 0.125
> 55 (referent group) 10 (53%) 9 (47%) – –
Gender (n = 382)
Male (referent group) 88 (36%) 156 (64%) – –
Female 34 (25%) 104 (75%) 1.67 (1.04–2.69) 0.034
Education (n = 381)
Completed ≥ 10 years school education (referent group) 94 (36%) 170 (64%) – –
Completed < 10 years school education 27 (23%) 90 (77%) 1.87 (1.12–3.12) 0.016
Main source of incomeb (n = 381)
Other (referent group) 111 (32%) 236 (68%) – –
Paid employment 10 (29%) 24 (71%) 1.17 (0.52–2.56) 0.695
Homelessc (n = 382)
No (referent group) 86 (32%) 183 (68%) – –
Yes 36 (32%) 77 (68%) 1.04 (0.64–1.69) 0.882
Substance use and use disorders
Past-month cocaine use (n = 381)
No (referent group) 112 (33%) 231 (67%) – –
Yes 9 (24%) 29 (76%) 1.49 (0.67–3.28) 0.326
Past-month (meth)amphetamine use (n = 376)
No (referent group) 69 (39%) 108 (61%) – –
Yes 50 (25%) 149 (75%) 1.90 (1.20–3.01) 0.006
Past-month heroin use (n = 379)
No (referent group) 52 (40%) 78 (60%) – –
Yes 68 (27%) 181 (73%) 1.81 (1.15–2.85) 0.011
Past-month morphine use (n = 379)
No (referent group) 98 (32%) 211 (68%) – –
Yes 24 (34%) 46 (66%) 1.05 (0.60–1.85) 0.862
Past-month oxycodone use (n = 378)
No (referent group) 96 (33%) 198 (67%) – –
Yes 25 (30%) 59 (70%) 1.28 (0.75–2.21) 0.366
Hazardous drinking (AUDIT-C) (n = 368)
No (referent group) 70 (31%) 159 (69%) – –
Yes 48 (35%) 91 (65%) 0.75 (0.48–1.19) 0.229
Life-time OAT
Ever been in methadone treatment (n = 380)
No (referent group) 24 (32%) 52 (68%) – –
Yes 97 (32%) 207 (68%) 0.98 (0.56–1.72) 0.950
Ever been in buprenorphine ± naloxone treatment (n = 381)
No (referent group) 57 (36%) 102 (64%) – –
Yes 64 (29%) 158 (71%) 1.26 (0.80–1.98) 0.311
Current treatment
Current OAT for opioid use disorder (n = 381)
No OAT (referent group) 36 (29%) 90 (71%) – –
(Continues)
Extended-release buprenorphine injections 5
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
Compared to those not currently receiving OAT, partic-
ipants currently receiving OAT were more likely to endorse
‘attend treatment services less frequently’ and less likely to
endorse ‘blocks the effects of other opioids’, ‘reduces the
need for willpower to stay in treatment and/or avoid using
other opioids’ and ‘decreases my risk of overdose’ as advan-
tages. There were no other differences in the reporting of
advantages or disadvantages according to current OAT sta-
tus (Supporting information, Appendix S6).
Among those who responded to the item regarding
willingness to change doctors to access XR-
buprenorphine treatment (n = 354; n = 48 missing
cases), 68% were willing to change doctors and almost
one-quarter (23%) were not willing to do so (10% ‘don’t
know’). Among participants in the total sample who
responded to the item regarding how far they were will-
ing to travel for treatment with XR-buprenorphine
(n = 388; n = 14 missing cases), 17% were ‘not
interested/not willing to travel at all’, 25% were willing
to travel up to 30 minutes, 34% 30–60 minutes, 10%
60–90 minutes and 14% more than 90 minutes. To place
this in context of current travel time for dosing, among
the 51% of current OAT who reported currently travelling
≥ 5 km for dosing (n = 133), 74% believed XR-
Table 1. (Continued)
Perceived XR-buprenorphine was a good
treatment option for them, n = 382a
Adjusted odds ratiosdNo/not sure
n = 122 (32%)
Yes
n = 260 (68%)
n (%) n (%) aOR (95% CI) P-value
Methadone 76 (36%) 138 (64%) 0.65 (0.39–1.06) 0.081
Buprenorphine ± naloxone 9 (22%) 32 (78%) 1.22 (0.52–2.86) 0.652
Counselling/psychologist/individual CBT sessions (n = 378)
No (referent group) 87 (32%) 184 (68%) – –
Yes 34 (32%) 73 (68%) 1.03 (0.63–1.67) 0.916
aSee Methods for exact item wording; n = 20 participants were missing data on this item. bMain source of income ‘Other’ includes: government benefits or
pension, being supported by someone else’s income, retirement fund, having no income and ‘other’ source of income. c‘Homeless’ includes primary, secondary
or tertiary homelessness [25]. dn = 69 cases missing data for this item. eAdjusted odds ratios (AOR) control for age and gender (with the exception of age
which controls for gender only, gender which controls for age only). OAT = opioid agonist treatment (methadone or buprenorphine ± naloxone). AUDIT = Al-
cohol Use Disorders Identification Test; CBT = cognitive–behavioural therapy.
Figure 1 Participant ratings of likelihood of using once-weekly/once-monthly XR-buprenorphine injections (%) [Colour figure can be viewed at
wileyonlinelibrary.com]
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buprenorphine was a good treatment option for them
(Table 2).
More than two-thirds of participants (69%) reported no
problems or concerns with potential differences in the
availability, flexibility and location of services providing this
treatment, and 71% reported no problems or concerns
with delivery of XR-buprenorphine via subcutaneous injec-
tion (Fig. 2). Almost one in four participants (23%) reported
‘minor’ or ‘major’ concerns about the blockade effects of
XR-buprenorphine (Fig. 2). There were no differences
according towhether or not participants were currently re-
ceiving OAT (Supporting information, Appendix S6).
DISCUSSION
Although previous studies have explored OAT client views
of XR-buprenorphine using small samples [21,22], this
study builds on this previous work by undertaking an in-
depth examination of demographic and clinical correlates
of these perceptions in a diverse sample of people who
Table 2 Current OAT clients’ perceptions that XR-buprenorphine would be a good treatment option for them, according to features of
their current OAT.
Perceived XR-buprenorphinewas a
good treatment option for them
(n = 255)b
Adjusted odds ratioscTotal
a
N = 266
No/not sure
n = 85 (33%)
Yes
n = 170 (67%)
n (%) n (%) n (%) aOR (95% CI) P-value
Currently receiving (n = 255):
Methadone (referent group) 224 (84%) 76 (36%) 138 (65%) – –
Buprenorphine ± naloxone 42 (16%) 9 (22%) 32 (78%) 1.50 (0.62–3.62) 0.365
Time in current treatment episode, years (n = 229)
< 1 68 (26%) 18 (27%) 49 (73%) 1.84 (0.95–3.55) 0.068
1–2 27 (10%) 4 (15%) 23 (85%) 3.93 (1.26–12.22) 0.018
≥ 2 (referent group) 166 (64%) 59 (38%) 97 (62%) – –
Location of last dispensed dose (n = 255)
Community pharmacy (referent group) 115 (43%) 44 (40%) 69 (61%) – –
Other setting (public or private clinic) 151 (57%) 41 (29%) 101 (71%) 1.64 (0.93–2.91) 0.089
Prescriber setting (n = 255)
Public clinic (referent group) 173 (65%) 53 (37%) 115 (63%) – –
Other setting 93 (35%) 32 (32%) 55 (69%) 0.76 (0.43–1.34) 0.340
Main opioid of concern at treatment entry (n = 252)
Heroin (referent group) 217 (83%) 68 (33%) 141 (68%) – –
Pharmaceutical opioids 46 (18%) 16 (37%) 27 (63%) 0.83 (0.40–1.73) 0.618
Dose adherence (n = 254)
Took all doses as directed in past 28 days (referent) 156 (59%) 51 (34%) 100 (66%) – –
Missed a scheduled dose in past 28 days 108 (41%) 33 (32%) 70 (68%) 0.97 (0.55–1.74) 0.936
Receiving unsupervised (take-home) dosesd (n = 254)
No (referent group) 132 (50%) 36 (28%) 95 (73%) – –
1–7 doses past month 26 (10%) 9 (38%) 15 (63%) 0.76 (0.27–2.13) 0.601
≥ 8 doses past month 106 (40%) 40 (40%) 59 (60%) 0.50 (0.27–0.93) 0.028
Out-of-pocket expenses for OAT (i.e. pharmacy, travel, and
prescriber fees) (n = 242)
None (referent group) 38 (16%) 13 (34%) 25 (66%) – –
$1–35 AUD per week 96 (40%) 34 (35%) 62 (65%) 0.93 (0.40–2.20) 0.874
≥ $35 AUD per week 110 (45%) 31 (29%) 77 (71%) 1.53 (0.65–3.59) 0.333
Travel requirements to receive OAT doses (n = 253)
0–5 km per day (referent group) 130 (49%) 52 (41%) 76 (59%) – –
≥ 5 km per day 133 (51%) 32 (26%) 93 (74%) 2.10 (1.20–3.65) 0.009
aN=266 participants reported currently receivingmethadone or buprenorphine; of these, n=255 responded to the item ‘Perceptions that XR-buprenorphine
was a good treatment option for them’. bSee Methods for exact item wording cAdjusted odds ratios controlled for age and gender. d‘Unsupervised (take-home)
doses’ = doses dispensed to the patient to take at home (i.e. no direct supervision of consumption by a clinician or pharmacist).
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regularly use opioids, with varied treatment experiences.
Consistent with previous studies [21,22], perceptions of
XR-buprenorphine were generally positive, with two-thirds
of the current study’s sample believing it would be a good
treatment option for them if it were available. Overall, less
frequent contact with treatment services was viewed posi-
tively by participants (endorsed as an advantage by 76%).
Although participants endorsed a range of advantages that
we identified prior to the study, additional advantages of
XR-buprenorphine were noted, including reducing the
burden of attendance for supervised dosing, increasing pri-
vacy for OAT clients and reducing stigma.
Participants who believed that XR-buprenorphine was
a good treatment option for them were more likely to re-
port: being younger (26–35 years versus > 55 years); be-
ing female; fewer years of school education; and past-
month heroin use and methamphetamine use. Neither
life-time nor current OATwere associatedwith participants
believing XR-buprenorphine would be a good treatment
option. The finding that women were more likely to find
this treatment option attractive is consistent with a grow-
ing body of research demonstrating that gender impacts
on treatment relevance, access and effectiveness, and that
women in particular are impacted by stigma, violence and
criminalization of substance use [27]. It is also consistent
with the qualitative reports in the current study indicating
that XR-buprenorphine offers advantages to carers of
young children, who are frequently women, by reducing
the burden of having to attend for dosing with children
present and providing parents with a degree of privacy re-
garding their drug treatment.
Previous studies have indicated that prior experience
with buprenorphine treatment is an important factor
influencing perceptions of buprenorphine [20] yet, in the
current study, neither life-time nor current methadone or
buprenorphine ± naloxone use were associated with par-
ticipants believing that XR-buprenorphine was a good
treatment option for them. Participants who reported re-
cent drug use (past-month heroin and methamphetamine
use and methamphetamine dependence), however, were
more likely to hold positive views of XR-buprenorphine.
Among current OAT recipients, believing that XR-
buprenorphine was a good treatment option for them
was associated with: treatment episodes of 1–2 years (ver-
sus ≥ 2 years); fewer take-away doses and greater travel
distance.
Many of these factors appear to be related to less stable
patterns of drug use, and are consistent with the percep-
tions that XR-buprenorphine may improve treatment ad-
herence and outcomes among those clients who find it
difficult to meet current treatment programme require-
ments and for whom illicit drug use persists. Alternatively,
factors such as greater travel distance and fewer unsuper-
vised doses make treatment inconvenient, and policy shifts
towards greater restrictions on unsupervised dosing in
some jurisdictions (e.g. [28]) may mean that this is an in-
creasing concern for OAT clients. Only 7% of participants
reported a preference for weekly XR-buprenorphine injec-
tions (with more than half the sample reporting ‘no prefer-
ence’ and 39% reporting a preference for monthly
injections), possibly reflecting ambivalence about the bur-
den of frequent attendance at drug treatment services. It
is interesting that more ‘stable’ OAT client profiles (e.g. re-
ceiving more unsupervised doses, treatment episodes lon-
ger than 1–2 years) were not associated with viewing
XR-buprenorphine as a good treatment option. It may be
that clients who are stable on OAT and have access to un-
supervised doses do not perceive additional benefits of XR-
buprenorphine.
In Australia, OAT [methadone and sublingual
buprenorphine (± naloxone)] are prescribed from a mix of
general practice (or office-based) and specialist settings,
with the majority of clients dispensed their medication in
community pharmacies. Although the government fully
subsidizes the cost of the medication, there is no govern-
ment remuneration to community pharmacies for dispens-
ing or supervision of dosing. This cost, approximately AUD
$30–70 per week, is passed on to OAT clients. The excep-
tion is where clients are accessing State-government
funded public clinics and this cost is covered, although dos-
ing in these settings occurs in only 7% of OAT clients na-
tionally [23]. Although the current study did not find an
association between OAT clients’ out-of-pocket costs and
perceptions of whether XR-buprenorphinemight be a good
treatment option for them, it is possible that participants
were not yet aware of the potential savings.
While overall perceptions of XR-buprenorphine were
positive, views on the benefits and disadvantages varied
among participants. Although reported less frequently,
participants endorsed important potential disadvantages,
such as concerns about the effectiveness of XR-
buprenorphine suppressing withdrawal symptoms for the
period between doses, the blockade effect and a sense of loss
of control over treatment. In addition to the potential dis-
advantages that we identified prior to the study, additional
disadvantages of XR-buprenorphine were noted by partici-
pants, including anxiety about the possible adverse effects,
pain management concerns and concerns that the injec-
tion may itself act as a ‘trigger’ for illicit opioid use.
A strength of this study is that it includes participants
who were currently engaged and non-engaged in OAT. A
limitation of the survey was that it assessed perceptions
and experiences of a range of different treatment ap-
proaches for opioid use disorder (e.g. residential rehabilita-
tion, mutual support groups, naltrexone, etc.) as well as
XR-buprenorphine. The initial description of XR-
buprenorphine provided to participants may have primed
for more positive responses, and perceptions need to be
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understood in this light. This study is also subject to the
usual limitations associated with cross-sectional survey de-
signs and convenience sampling methods. Study sites did
not routinely collect information about numbers examined
for eligibility, confirmed eligible and included in the study,
and we are unable to report these details. However, the de-
mographic characteristics of the current study’s sample
are consistent with those of other large Australian studies
of people with OUD (i.e. the majority male, typically aged
early 40s, with the majority of OAT clients receiving meth-
adone) [23,29]. The study was conducted in a setting
where there is a strong emphasis on the supervised dosing
of medication in OAT. The findings on the attractiveness of
XR-buprenorphinemay be unique to this context, andmay
not generalize to other countries or settings where there
are fewer restrictions placed on buprenorphine treatment.
In addition, although more than half the sample were cur-
rently receiving methadone or buprenorphine, the sample
of buprenorphine clients (n = 42) was relatively small, lim-
iting both power to detect differences and representative-
ness. Finally, this study was conducted prior to the
implementation of XR-buprenorphine formulations in
Australia, so participants were commenting on hypotheti-
cal scenarios and anticipated preferences, benefits and dis-
advantages. The extent to which these reflect views of XR-
buprenorphine-experienced clients is yet to be established.
Despite these limitations, this study provides important in-
sights into client perspectives on this important and poten-
tially transformative treatment development.
Clients’ perceptions and concerns are essential in
informing understanding of who will (and will not) find
XR-buprenorphine an attractive treatment option. They
are also important in developing relevant and targeted
communication strategies. Clients may be anxious about
Table 3 Perceived advantages and disadvantages of XR-
buprenorphine (n = 392).
%
Advantages
Attend treatment services less frequently 76
Gives me more time to do other things 69
Allows travel for work or holidays 66
Prevents cravings for opioids 64
Feel in control of my treatment 63
Suppresses withdrawal symptoms for a long time 62
Could avoid regular contact with other people in drug
treatment
59
Blocks the effects of other opioids 54
Reduces the need for willpower to stay in treatment and/or
avoid using other opioids
54
Decreases my risk of overdose (safety) 52
Disadvantages
Might not hold people for the whole period between doses 40
Blocks the effects of other opioids 26
Less flexibility in treatment 17
Feel less in control of my treatment 16
Don’t like the idea of having the drug/depot inside me for a
long time
16
Reduced opportunity to attend treatment services for dosing 12
Reduced opportunity to have regular contact with other
people in drug treatment
7
10 cases missing data for this section.
Figure 2 Participants’ reports of the extent to which different features of treatment with XR-buprenorphine injections raised problems or concerns
(%) [Colour figure can be viewed at wileyonlinelibrary.com]
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the introduction of new OAT formulations, and previous
research indicates that the way in which change is com-
municated and managed may impact on their experience.
One study has found that in jurisdictions where transfer
from buprenorphine–naloxone tablets to the film formula-
tion was mandated, clients reported more adverse effects
of medication than in jurisdictions with less stringent poli-
cies [19]. Australian OAT guidelines recommend that cli-
ent preferences are taken into account in choosing
medications [13]. These findings may act as a guide for
those discussions that are had on an individual basis. Pro-
active communication strategies involving peers may help
manage anxiety regarding changing buprenorphine for-
mulations among clients.
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